托吡酯、卡马西平治疗老年痛性周围神经病的临床疗效及安全性观察

Observation on clinical efficacy and safety of topiramate and carbamazepine in the treatment of painful peripheral neuropathy in the elderly

目的比较老年痛性周围神经病患者采用托吡酯、卡马西平的疗效及安全性。方法选取90例老年痛性周围神经病患者,按照用药不同分为A组(43例)和B组(47例)。A组给予托吡酯治疗,B组给予卡马西平治疗。对比两组患者治疗效果、不良反应发生情况、匹兹堡睡眠质量指数量表(PSQI)评分。结果A组治疗总有效率为90.70%,明显高于B组的74.47%,差异具有统计学意义(P<0.05)。A组治疗期间不良反应发生率为4.65%,显著低于B组的4.65%,差异具有统计学意义(P<0.05)。两组治疗前PSQI评分对比,差异无统计学意义(P>0.05);治疗12周后,两组PSQI评分均显著低于治疗前,而A组明显低于B组,差异具有统计学意义(P<0.05)。结论针对老年痛性周围神经病患者,采用托吡酯治疗,相比卡马西平,效果更好,安全性更高,因而可作为治疗此病的首选药。

Objective To compare the efficacy and safety of topiramate and carbamazepine in the treatment of painful peripheral neuropathy in the elderly.Methods A total of 90 elderly patients with painful peripheral neuropathy were divided into group A(43 cases)and group B(47 cases)according to different medication.Group A was treated with topiramate,and group B was treated with carbamazepine.The therapeutic effect,occurrence of adverse reactions,Pittsburgh Sleep Quality Index(PSQI)score were compared between the two groups.Results The total effective rate of group A was 90.70%,which was obviously higher than 74.47% of group B,and the difference was statistically significant(P<0.05).The incidence of adverse reactions during treatment of group A was 4.65%,which was significantly lower than 4.65% of group B,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in PSQI score between the two groups(P>0.05).After 12 weeks of treatment,the PSQI score of the two groups were significantly lower than those before treatment,and group A was obviously lower than group B.All the difference was statistically significant(P<0.05).Conclusion For elderly patients with painful peripheral neuropathy,topiramate therapy is more effective and safer than carbamazepine,so it can be used as the first choice for the treatment of this disease.